RxDoctor Payments Data

Deborah Goldstein

Infectious Disease · Washington, DCNPI 1457502460

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $946 of the $1,350 with a category attached, or 70.1%. Merck accounts for 98.6% of it on its own, with 1 other manufacturer making up the rest.

$1,350in general payments, 2019–2025

Across 13 payments — averaging $103.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1K
  • Ferring Pharmaceuticals Inc.$18
$706,669in research payments, 2019–2025

Across 261 payments — averaging $2707.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$224K
  • Merck$223K
  • Viiv Healthcare Company$205K
  • Amgen$27K
  • Janssen Research & Development, LLC$23K
  • GSK$5K

What the payments were for

  • Travel & lodging$94670%
  • Food & beverage$40430%

General payments by program year

20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck12$1,332
Ferring Pharmaceuticals Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,350 in reported general payments places this provider in the 70th percentile of 74 infectious disease providers in District of Columbia.

See all infectious disease providers in District of Columbia →

Other infectious disease in Washington

See the full list for District of Columbia →

Where these figures come from

Is this you, or does something look wrong? →